Examination of the pharmacokinetics and differential inhibition of cyclooxygenase isoenzymes in New Zealand white rabbits (Oryctolagus cuniculus) by the Non-Steroidal anti-inflammatory Robenacoxib
© 2022 John Wiley & Sons Ltd..
Effective rabbit analgesia is challenging, and there are few studies available on the newer COX-2 selective NSAIDs, such as robenacoxib. This study aimed to establish the pharmacokinetics of oral and subcutaneous robenacoxib, describe its inhibitory actions on COX enzymes, and develop dosing, using six healthy New Zealand white rabbits. Pharmacokinetics were determined from plasma concentrations after oral administration of robenacoxib (0.83-0.96 mg/kg) and also after subcutaneous administration (2 mg/kg). The inhibitory actions of robenacoxib were evaluated by measuring plasma concentrations of thromboxane B2 (TBX2 ) and prostaglandin E2 (PGE2 ) as surrogate markers of cyclooxygenase enzyme isoform inhibition. The mean maximum concentration for oral and subcutaneous administration was 0.23 μg/ml and 5.82 μg/ml, respectively. Oral robenacoxib administration did not demonstrate a significant difference between any time point for PGE2 or TBX2 , though subcutaneous administration did for both. There was no significant difference in PGE2 or TBX2 concentrations at any time point when comparing subcutaneous versus oral routes. Although the results support that plasma robenacoxib exceeds the therapeutic levels compared to dogs and cats, there was little significance in the difference in the changes associated with COX-1 and COX-2 inhibition. Further studies are warranted to determine appropriate dosing, safety, and efficacy in rabbits.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Journal of veterinary pharmacology and therapeutics - 46(2023), 2 vom: 26. März, Seite 103-111 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jeffrey, Alison [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.03.2023 Date Revised 07.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jvp.13105 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349907692 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349907692 | ||
| 003 | DE-627 | ||
| 005 | 20231226043738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jvp.13105 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM349907692 | ||
| 035 | |a (NLM)36478376 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jeffrey, Alison |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Examination of the pharmacokinetics and differential inhibition of cyclooxygenase isoenzymes in New Zealand white rabbits (Oryctolagus cuniculus) by the Non-Steroidal anti-inflammatory Robenacoxib |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2023 | ||
| 500 | |a Date Revised 07.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons Ltd. | ||
| 520 | |a Effective rabbit analgesia is challenging, and there are few studies available on the newer COX-2 selective NSAIDs, such as robenacoxib. This study aimed to establish the pharmacokinetics of oral and subcutaneous robenacoxib, describe its inhibitory actions on COX enzymes, and develop dosing, using six healthy New Zealand white rabbits. Pharmacokinetics were determined from plasma concentrations after oral administration of robenacoxib (0.83-0.96 mg/kg) and also after subcutaneous administration (2 mg/kg). The inhibitory actions of robenacoxib were evaluated by measuring plasma concentrations of thromboxane B2 (TBX2 ) and prostaglandin E2 (PGE2 ) as surrogate markers of cyclooxygenase enzyme isoform inhibition. The mean maximum concentration for oral and subcutaneous administration was 0.23 μg/ml and 5.82 μg/ml, respectively. Oral robenacoxib administration did not demonstrate a significant difference between any time point for PGE2 or TBX2 , though subcutaneous administration did for both. There was no significant difference in PGE2 or TBX2 concentrations at any time point when comparing subcutaneous versus oral routes. Although the results support that plasma robenacoxib exceeds the therapeutic levels compared to dogs and cats, there was little significance in the difference in the changes associated with COX-1 and COX-2 inhibition. Further studies are warranted to determine appropriate dosing, safety, and efficacy in rabbits | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Oryctolagus cuniculus | |
| 650 | 4 | |a COX-2 selective inhibitor | |
| 650 | 4 | |a Robenacoxib | |
| 650 | 4 | |a pharmacology | |
| 650 | 4 | |a rabbit | |
| 650 | 7 | |a Cyclooxygenase 2 |2 NLM | |
| 650 | 7 | |a EC 1.14.99.1 |2 NLM | |
| 650 | 7 | |a robenacoxib |2 NLM | |
| 650 | 7 | |a Z588009C7C |2 NLM | |
| 650 | 7 | |a Isoenzymes |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Phenylacetates |2 NLM | |
| 650 | 7 | |a Cyclooxygenase 1 |2 NLM | |
| 650 | 7 | |a EC 1.14.99.1 |2 NLM | |
| 650 | 7 | |a Diphenylamine |2 NLM | |
| 650 | 7 | |a 9N3CBB0BIQ |2 NLM | |
| 650 | 7 | |a Dinoprostone |2 NLM | |
| 650 | 7 | |a K7Q1JQR04M |2 NLM | |
| 650 | 7 | |a Cyclooxygenase 2 Inhibitors |2 NLM | |
| 700 | 1 | |a Gardhouse, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Kleinhenz, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Hocker, Samuel E |e verfasserin |4 aut | |
| 700 | 1 | |a Weeder, Mikaela |e verfasserin |4 aut | |
| 700 | 1 | |a Montgomery, Shawnee R |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yuntao |e verfasserin |4 aut | |
| 700 | 1 | |a Porting, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Rooney, Tess |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of veterinary pharmacology and therapeutics |d 1993 |g 46(2023), 2 vom: 26. März, Seite 103-111 |w (DE-627)NLM012964816 |x 1365-2885 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2023 |g number:2 |g day:26 |g month:03 |g pages:103-111 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jvp.13105 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2023 |e 2 |b 26 |c 03 |h 103-111 | ||